Baker McKenzie advised Simulands AG ("Simulands"), a Swiss creator of simulation devices for cardiovascular medicine, when obtaining a EUR 10 million investment from healthcare private equity firm SHS Capital.

Simulands plans to accelerate its commercialization strategy for its cardiac intervention training equipment, which is important and appropriate for the mission-critical nature of this field.

Founded in Zurich in 2019, Simulands has been growing rapidly, already establishing a strong reputation for its medical simulation training tools.

Baker McKenzie Switzerland advised Simulands on all legal aspects of the deal.

Led by M&A Partner Manuel Meyer, the Baker McKenzie team included Christian Rioult and Hesam Mirzai (associates, M&A).

Explore Our Newsroom